ASCO GU 2025 | Dr. Thomas Powles: EV+P Regimen Redefines Platinum-Based Chemotherapy, Setting a New First-Line Standard for Urothelial Cancer

ASCO GU 2025 | Dr. Thomas Powles: EV+P Regimen Redefines Platinum-Based Chemotherapy, Setting a New First-Line Standard for Urothelial Cancer

Urothelial carcinoma (UC) is the second most common malignancy of the urinary system, characterized by poor prognosis and low five-year survival rates. For decades, platinum-based chemotherapy has remained the standard first-line treatment for locally advanced or metastatic urothelial carcinoma (la/mUC). However, limited clinical benefit and poor tolerability have left many unmet treatment needs.
Dr. Neeraj Agarwal: Talazoparib Plus Enzalutamide Extends First-Line OS to Nearly Four Years, Pioneering a New Era in Precision Treatment for mCRPC

Dr. Neeraj Agarwal: Talazoparib Plus Enzalutamide Extends First-Line OS to Nearly Four Years, Pioneering a New Era in Precision Treatment for mCRPC

The 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) was held from February 13 to 15 in San Francisco, California, bringing together leading experts and researchers in the field of genitourinary oncology. Among the key highlights was the final overall survival (OS) data from the TALAPRO-2 trial, presented by Dr. Neeraj Agarwal from the Huntsman Cancer Institute (HCI), University of Utah. The study drew widespread attention as it not only addressed a critical gap in first-line treatment for metastatic castration-resistant prostate cancer (mCRPC) using a PARP inhibitor in combination with next-generation hormonal therapy (NHT) but also reinforced the growing role of precision medicine in prostate cancer treatment.
ASCO GI 2025 | Dr. Scott Kopetz: EC + FOLFOX Regimen Significantly Improves Response Rates in mCRC, Delivering Rapid and Durable Efficacy

ASCO GI 2025 | Dr. Scott Kopetz: EC + FOLFOX Regimen Significantly Improves Response Rates in mCRC, Delivering Rapid and Durable Efficacy

The 2025 ASCO Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25, showcasing the latest advances in gastrointestinal cancer research and treatment strategies. One of the most notable studies was the BREAKWATER trial (Abstract #16), which focused on BRAF V600E-mutant metastatic colorectal cancer (mCRC). This study demonstrated a significant improvement in response rates and durable efficacy, positioning EC + FOLFOX as a promising first-line treatment option for this high-risk patient group. The findings also provide further evidence for the role of precision medicine in mCRC, reinforcing the need to integrate targeted therapy into earlier treatment settings.
EASL Liver Cancer Summit | HNF1A Gene: Unlocking the “Key” to Hepatocellular Carcinoma Risk – Exclusive Interview with Professor Mohamed Abdel Samie

EASL Liver Cancer Summit | HNF1A Gene: Unlocking the “Key” to Hepatocellular Carcinoma Risk – Exclusive Interview with Professor Mohamed Abdel Samie

Hepatocellular carcinoma (HCC), one of the most lethal tumors globally, has long been a research hotspot due to its complex pathogenesis involving interactions between genetics, metabolism, and viral infections. Recently, at the 2025 EASL Liver Cancer Summit held in Paris, France, a study by Professor Mohamed Abdel Samie's team from the Department of Hepatology and Gastroenterology at the National Liver Institute, Menoufia University, Egypt, revealed the crucial role of the HNF1A genotype in HCC risk. Oncology Frontier invited Professor Mohamed Abdel Samie to discuss the potential value of this gene in HCC screening and the impact of metabolic factors. We look forward to future personalized treatment strategies targeting specific genotypes bringing new breakthroughs in the prevention and treatment of HCC.
ASCO GI 2025 | Dr. Zhi Peng: Five-Year Survival Benefits from CheckMate 649 Bring New Hope for a Cure in Gastric Cancer Patients

ASCO GI 2025 | Dr. Zhi Peng: Five-Year Survival Benefits from CheckMate 649 Bring New Hope for a Cure in Gastric Cancer Patients

CheckMate 649 is the first global Phase III trial to successfully evaluate a first-line immunotherapy regimen (nivolumab + chemotherapy) for advanced gastric cancer. The study’s primary results were first unveiled at the 2020 European Society for Medical Oncology (ESMO) Congress, and the pre-specified China subgroup data were presented for the first time at the 2021 American Association for Cancer Research (AACR) meeting. The findings demonstrated even greater benefits in Chinese patients compared to the global population, generating significant academic interest and establishing first-line immunotherapy plus chemotherapy as the standard of care for advanced gastric cancer in China. Today, nivolumab in combination with chemotherapy has been approved as a first-line treatment for advanced or metastatic gastric cancer (GC), gastroesophageal junction cancer (GEJC), and esophageal adenocarcinoma (EAC) in more than 50 countries, including the United States and China.